More evidence has emerged of the benefits of CGM use in the high-risk populations of adolescent and young adults (AYA) and older adults with type 1 diabetes. A US study, published in JAMA, randomised 153 young people 14-24 years with sub-optimal glycaemic control (HbA1c 7.5-10.9%, 58-96 mmol/mol) to either CGM or to remaining on standard ...
Type 1 diabetes
CGM proving its worth in high-risk T1D groups
By Mardi Chapman
18 Jun 2020